Year None202220212020 Dec 01, 2022 Lyell Immunopharma to Participate in BofA Securities Biotech Conference Nov 10, 2022 Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series Nov 08, 2022 Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results Nov 07, 2022 Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors Nov 02, 2022 Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference Oct 06, 2022 Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors Oct 05, 2022 Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting Sep 28, 2022 Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer Sep 12, 2022 Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022 Aug 30, 2022 Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 20
